6Rangel-Frausto MS, Pittet D, Costigan M, et al. The natural history of the syslemic inflammatory response syndrome (SIRS): a prospective study [ J ]. JAMA, 1995, 273(2):117-23.
7Vervloet MG, Thijs LG, Hack CE. Derangement of eoagulation and fibrinolysis in crilically ill patienls wilb sepsis and seplic shock[J]. Semi Thro Heam, 1998, 24(1):33-44.
8Bone RC, Balk RA, Cerra FB, el al. Definitions far sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM consensus conference committee [J]. Chest, 1992, 101(6):1644-1655.
9Ymamaoto K, Loskutoff DJ. Fibrin deposition in tissues from en- dotoxin-lreated Mice Correlates with decreases in the expression of urokinase-type but not tissue-type Plasminogen activator[J]. J Clinical investigation, 1996, 97(11):2440-2451.
10Bernard GR, Vinceni JL, Lalerre PF, et al. Efficacy and safely of recombinant human activated protein C for severe sepsis [J]. New Engl J Med, 2001,344(10):699-709.
1Van den Berghe G, Wilmer A, Hermans G,et al. Intensive insulintherapy in the medicai ICU. N Engl J Med, 2006, 349(354):449-461.
2Finfer S, Chittock DR, Su SY, et al. Intensive versus conventionalglucose control in critically ill patients. N Engl J Med, 2009,352(360): 1283-1297.
3Bemaed GR, Vincent JL, Laterre PF, et al. Efficacy and safety ofrecombinant human activated protein C for severe sepsis. N End JMed, 2001,344(10):699-709.
